Nuveen
CARM

Nuveen’s Carisma Therapeutics CARM Stock Holding History

Nuveen’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-102,702
Closed -$233K – 3345
2024
Q1 		$233K Hold
102,702
– – ﹤0.01% 3151
2023
Q4 		$301K Buy
102,702
+2,914
+3% +$8.66K ﹤0.01% 3146
2023
Q3 		$422K Hold
99,788
– – ﹤0.01% 2898
2023
Q2 		$875K Buy
+99,788
New +$543K ﹤0.01% 2715
2022
Q2 		– Sell
-26,322
Closed -$3.11M – 3275
2022
Q1 		$3.11M Hold
26,322
– – ﹤0.01% 2300
2021
Q4 		$3.11M Sell
26,322
-12,500
-32% -$252K ﹤0.01% 2359
2021
Q3 		$4.58M Sell
38,822
-518
-1% -$24.9K ﹤0.01% 2264
2021
Q2 		$3.63M Buy
+39,340
New +$2.51M ﹤0.01% 2407

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $104M AUM
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nuveen's CARM Position: Q2 2024 in Review

Nuveen sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 102,702 shares — an estimated $233K sold.

Nuveen first reported a position in CARM in Q2 2021 and held it in 8 quarters. The position peaked at $4.58M in Q3 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

  • Nuveen reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 102,702 Carisma Therapeutics shares in Q2 2024, an estimated $233K.
  • Nuveen first reported a position in Carisma Therapeutics in Q2 2021 and held it in 8 quarters.
  • Nuveen's Carisma Therapeutics position peaked at $4.58M in Q3 2021.
  • 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.